医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mary Kay Inc Presents New Findings on an Antioxidant Blend That Can Reduce the Visible Effects of Pollution and Aging on Skin

2023年09月20日 AM12:00
このエントリーをはてなブックマークに追加


 

DALLAS

Mary Kay Inc., a global leader in skin care innovation, recently revealed breakthrough research on a treatment that diminishes the visible effects of pollution and aging on human skin. The findings, which Mary Kay shared at the first International Societies for Investigative Dermatology (ISID) Meeting, significantly improved skin firmness and the appearance of fine lines and wrinkles over the course of the study.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919497711/en/

“Mary Kay scientists have spent years researching the latest ingredient innovations to best defend against free radicals and help delay the onset of premature skin aging," said Dr. Lucy Gildea, Chief Innovation Officer, Product & Science at Mary Kay. (Photo: Mary Kay Inc.)

“Mary Kay scientists have spent years researching the latest ingredient innovations to best defend against free radicals and help delay the onset of premature skin aging,” said Dr. Lucy Gildea, Chief Innovation Officer, Product & Science at Mary Kay. (Photo: Mary Kay Inc.)

“Mary Kay scientists have spent years researching the latest ingredient innovations to best defend against free radicals and help delay the onset of premature skin aging from environmental and lifestyle stressors such as car exhaust and air pollution,” said Dr. Lucy Gildea, Chief Innovation Officer, Product & Science at Mary Kay.

The research was also published in the International Journal of Cosmetic Science.

Scientists at Mary Kay have been investigating the effects of air pollution on skin through multiple academic collaborations since 2016. Previous efforts have analyzed the biochemical responses of human skin cells to various forms of pollution, including diesel exhaust and urban air pollution. Key findings revealed a proprietary blend of antioxidants reduces those responses.

“There is no remaining doubt that air pollution contributes to skin aging,” said Dr. Jean Krutmann, a pioneer of environmental medicine, Professor of Dermatology and Director of the IUF – Leibniz Research Institute for Environmental Medicine in Düsseldorf, Germany. He has been leading research to determine the effect of air pollution on human skin since publication of the key paper in 2010 to show the effect of airborne particle exposure on skin aging.

The findings presented at the 2023 ISID are just the latest efforts by Mary Kay to reinforce the brand’s long-standing commitment to advancing research and development in skin health and beauty. Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio.

About Mary Kay

Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230919497711/en/

CONTACT

Mary Kay Inc. Corporate Communications

marykay.com/newsroom

972.687.5332 or media@mkcorp.com

同じカテゴリーの記事 

  • Stonepeak to Acquire Arvida Group
  • European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
  • JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
  • Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
  • ベイジーン、アーロン・ローゼンバーグ氏を最高財務責任者に任命